Qualigen Therapeutics’ Acquisition of NanoSynex

Horn & Co. represented Nanosynex Ltd. in the deal.

Qualigen Therapeutics, Inc. has completed the acquisition of a majority stake in NanoSynex Ltd., an Israeli-based developer of next generation diagnostics technology.

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics.

The Horn & Co. team was led by Uri Dotan (Picture) and Shiran Glantz.

Involved fees earner: Uri Dotan – Horn & Co. Law; Shiran Glantz – Horn & Co. Law;

Law Firms: Horn & Co. Law;

Clients: NanoSynex;